Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejim.2006.05.002 http://scihub22266oqcxt.onion/10.1016/j.ejim.2006.05.002 17098597!?!17098597 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17098597&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Intern+Med 2006 ; 17 (7): 505-7 Nephropedia Template TP {{tp|p=17098597|t=2006. Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment |pdf=|usr=}}{{17098597}} gab.com Text Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment JO: Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=17098597 #FOAvip A patient with primary biliary cirrhosis and associated refractory immune thrombocytopenic purpura was treated with 4 weekly courses of rituximab, a monoclonal antibody targeting B-cell surface antigen CD20. Her thrombocyte count and even cholestatic liver function tests improved. However, 17 weeks after rituximab treatment, she developed severe neutropenia (absolute neutrophil count 0.23x10(3)/mul) and recurrent thrombocytopenia with abnormal bone marrow of all three lineages. Although delayed-onset neutropenia has been reported after rituximab, reactivated viral infections have also been encountered. Parvovirus B19 was suspected and confirmed as the cause of neutropenia in our patient. The patient was supported by GCSF treatment and recovered uneventfully after several weeks. Neutropenia after rituximab can also be the predominant manifestation of reactivated parvovirus B19 infection and have a favorable prognosis. Twit Text FOAVip Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment ????Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=17098597 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=17098597 #FOAvip English Wikipedia <ref>{{Cite pmid|17098597}}</ref> Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment #MMPMID17098597 Klepfish A; Rachmilevitch E; Schattner A Eur J Intern Med 2006[Nov]; 17 (7): 505-7 PMID17098597show ga A patient with primary biliary cirrhosis and associated refractory immune thrombocytopenic purpura was treated with 4 weekly courses of rituximab, a monoclonal antibody targeting B-cell surface antigen CD20. Her thrombocyte count and even cholestatic liver function tests improved. However, 17 weeks after rituximab treatment, she developed severe neutropenia (absolute neutrophil count 0.23x10(3)/mul) and recurrent thrombocytopenia with abnormal bone marrow of all three lineages. Although delayed-onset neutropenia has been reported after rituximab, reactivated viral infections have also been encountered. Parvovirus B19 was suspected and confirmed as the cause of neutropenia in our patient. The patient was supported by GCSF treatment and recovered uneventfully after several weeks. Neutropenia after rituximab can also be the predominant manifestation of reactivated parvovirus B19 infection and have a favorable prognosis. ?Parvovirus B19 reactivation presenting as neutropenia after rituximab (epmc).pdf DeepDyve Pubget Overpricing